Biosimilar Portfolio

About Ache Laboratorios Farmaceuticos

A leading Brazilian pharmaceutical company developing and commercializing prescription and OTC medicines across multiple therapeutic areas.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals has evolved from its 1977 founding into a diversified, global pharmaceutical enterprise with a strategic focus on innovation and accessibility. Under the leadership of Chairman & Managing Director Glenn Saldanha, the company has built significant capabilities in R&D, biologics, and complex generics, supported by a robust pipeline of 25+ candidates and a global commercial footprint. Its strategy centers on advancing a focused pipeline in respiratory, dermatology, and oncology through its biotech arm Ichnos Glenmark Innovation (IGI), while simultaneously scaling its generics and branded formulations business across emerging and developed markets.

About Laboratorios Farmaceuticos Rovi

Laboratorios Farmaceuticos Rovi is a publicly-traded Spanish pharmaceutical company with a mission to develop, manufacture, and commercialize innovative therapies, particularly in biosimilars and low molecular weight heparins. The company has achieved significant scale through its dual business model, combining a profitable specialty pharma division with a strategic CDMO arm that serves third-party clients. Its strategy focuses on R&D investment in biosimilars as a core growth engine, while expanding its international commercial footprint and manufacturing capabilities to capitalize on high-value market opportunities.

About Dermapharm

Dermapharm is a mission-driven company focused on providing high-quality, affordable pharmaceutical products, primarily in dermatology and adjacent therapeutic areas. Its key achievements include building a robust portfolio through strategic acquisitions (e.g., Allergopharma, Hübner) and establishing a fully integrated model from development to sales. The company's strategy centers on lifecycle management of established molecules, operational excellence in manufacturing, and leveraging its dual revenue streams from proprietary products and parallel imports for sustainable growth.

Therapeutic Areas